marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-07-2024
SpringWorks Therapeutics Balance Sheet 2011-2024 | SWTX
Annual Balance Sheet SpringWorks Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-169 M | -62.2 M | -103 M | - | -328 M | -45.6 M | -10.3 M | - | - | - | - | - | - |
Long Term Debt |
6 M | 4.77 M | 129 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
1.06 M | 483 K | 1.16 M | 1.38 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 789 K | 64.1 M | 12.6 M | - | - | - | - | - | - |
Total Current Liabilities |
78.2 M | 51 M | 30 M | 17.6 M | 12 M | - | - | - | - | - | - | - | - |
Total Liabilities |
99.6 M | 72 M | 30.1 M | 19.1 M | 12.8 M | 67.8 M | 13.2 M | - | - | - | - | - | - |
Deferred Revenue |
4.14 M | 3.31 M | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-895 M | -570 M | -293 M | - | -73 M | -22.5 M | -4.64 M | - | - | - | - | - | - |
Total Assets |
726 M | 630 M | 452 M | 576 M | 335 M | 48.4 M | 10.6 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
176 M | 67.5 M | 105 M | 148 M | 328 M | 46.2 M | 10.3 M | - | - | - | - | - | - |
Book Value |
626 M | 558 M | 422 M | 557 M | 322 M | -19.4 M | -2.62 M | - | - | - | - | - | - |
Total Shareholders Equity |
626 M | 558 M | 422 M | 557 M | 322 M | -19.4 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet SpringWorks Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
6.1 M | 5.58 M | 6 M | 6.17 M | 6.8 M | 6.66 M | 4.77 M | 5 M | - | 5.54 M | 129 K | 367 K | 701 K | 1.03 M | 1.36 M | 1.36 M | 1.36 M | 1.36 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
60.6 M | 89.4 M | 99.6 M | 72.8 M | 65.9 M | 62.3 M | 72 M | 69.2 M | - | 28.8 M | 30.1 M | 28.6 M | 23.8 M | 19.9 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 4.83 M | 4.83 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | 4.65 M | 4.14 M | 3.24 M | 2.36 M | 1.69 M | 3.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.02 B | -982 M | -895 M | -801 M | -721 M | -643 M | -570 M | -496 M | - | -354 M | -293 M | -236 M | -195 M | -148 M | -119 M | -119 M | -119 M | -119 M | -73 M | -73 M | -73 M | -73 M | -22.5 M | -22.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
617 M | 657 M | 726 M | 468 M | 517 M | 569 M | 630 M | 682 M | - | 406 M | 452 M | 495 M | 520 M | 555 M | 576 M | 576 M | 576 M | 576 M | 335 M | 335 M | 335 M | 335 M | 48.4 M | 48.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
79.9 M | 118 M | 176 M | 98.9 M | 116 M | 103 M | 67.5 M | 477 M | 70.1 M | 82.5 M | 104 M | 94.4 M | 84.6 M | 95.4 M | 147 M | 147 M | 147 M | 147 M | 328 M | 328 M | 328 M | 328 M | 45.6 M | 45.6 M | - | - | 10.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
557 M | 567 M | 626 M | 395 M | 451 M | 507 M | 558 M | 612 M | - | 377 M | 422 M | 467 M | 497 M | 535 M | 557 M | 557 M | 557 M | 557 M | 322 M | 322 M | 322 M | 322 M | 43.6 M | 43.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
557 M | 567 M | 626 M | 395 M | 451 M | 507 M | 558 M | 612 M | 326 M | 377 M | 422 M | 467 M | 497 M | 535 M | 557 M | 557 M | 557 M | 557 M | 322 M | 322 M | 322 M | -20.5 M | -19.4 M | -19.4 M | -8.61 M | - | -2.62 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency